Idiopathic Inflammatory Myopathies Clinical Trial
Official title:
CARTIMMUNE: A Single-Center Study of Patients With Autoimmune Diseases Receiving an Autologous Fully-Human Anti-CD19 Chimeric Antigen Receptor T-Cell (KYV 101)
The purpose of this study is to assess the safety, tolerability, and clinical activity of KYV 101 (a fully-human anti-CD19 CAR T-cell therapy) in adult subjects with B cell-driven autoimmune diseases. The trial anticipates enrolling participants to reach a maximum of 24 participants who will receive 1 dose of KYV-101 and will be followed for 2 years.
The purpose of this study is to assess the safety, tolerability, and clinical activity of KYV 101 (a fully-human anti-CD19 CAR T-cell therapy) in 24 adult subjects with B cell-driven autoimmune diseases. The diseases under study include: idiopathic necrotizing myopathy (INM) consisting of dermatomyositis (DM), necrotizing myopathy, anti-HMGCoA-associated myopathy, and polymyositis (PM), diffuse cutaneous systemic sclerosis (dcSSc), systemic lupus erythematosus (SLE) with nephritis, and ANCA-associated vasculitis (AAV). Six participants in each autoimmune disease group for a total of 24 participants will receive a single dose of 1.0×10[8] CAR+ T cells. Participants will be followed under this protocol for 2 years. Lymphodepleting chemotherapy of cyclophosphamide (CYC) 300 mg/m2 and fludarabine (FLU) 30 mg/m2 intravenously (IV) daily for 3 days will be administered 5 to 7 days prior to administration of KYV-101. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05833711 -
Study Evaluating Efficacy and Safety of Froniglutide (PF1801) in Patients With Idiopathic Inflammatory Myopathy
|
Phase 2 | |
| Recruiting |
NCT04561557 -
Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous System
|
Early Phase 1 | |
| Completed |
NCT04208464 -
JAK 1/2 Inhibitor, Baricitinib, in the Treatment of Adult IIM
|
Phase 2 | |
| Completed |
NCT03267277 -
Sodium Thiosulfate for Treatment of Calcinosis Associated With Juvenile and Adult Dermatomyositis
|
Phase 2/Phase 3 | |
| Recruiting |
NCT06316076 -
Safety and Efficacy Study of CD19-CAR-DNT Cells in Autoimmune Diseases
|
Phase 1 | |
| Not yet recruiting |
NCT06350110 -
Fourth-gen CAR T Cells Targeting BCMA/CD19 for Refractory Systemic Lupus Erythematosus (SLE)
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05879419 -
Recombinant Herpes Zoster Vaccine in Patients With Autoimmune Rheumatic Diseases
|
Phase 4 | |
| Recruiting |
NCT04792931 -
Adult Autoimmune Myopathies (MAIA)
|
N/A | |
| Not yet recruiting |
NCT06417398 -
Preliminary Clinical Study of UTAA09 Injection in the Treatment of Relapsed/Refractory Autoimmune Diseases
|
Early Phase 1 | |
| Not yet recruiting |
NCT06285539 -
Drug Rediscovery for Rare Immune Mediated Inflammatory Diseases
|
Phase 2 | |
| Recruiting |
NCT04664465 -
PRediction Of DIverse Glucocorticoids toxIcity OUtcomeS
|
||
| Recruiting |
NCT05400889 -
Clinical Characteristics and Mechanism Research of Inhibitors of Janus Kinase in the Idiopathic Inflammatory Myopathies
|
Phase 2 | |
| Completed |
NCT03918356 -
Application of Electrical Impedance Myography (EIM) as a Potential Biomarker of Idiopathic Inflammatory Myopathies
|
N/A | |
| Completed |
NCT00341679 -
Studies of the Natural History and Pathogenesis of Autoimmune/Connective Tissue Diseases
|
||
| Recruiting |
NCT05952531 -
Characterizing Myositis With 68Ga-FAPI PET/CT
|
Early Phase 1 | |
| Recruiting |
NCT05200702 -
Assessment of Safety and Acute Effects of a Knee-hip Powered Soft Exoskeleton in Patients With Neuromuscular Disorders
|
N/A | |
| Completed |
NCT03092167 -
Physical Training in Patients With Idiopathic Inflammatory Myopathies
|
N/A | |
| Recruiting |
NCT03092180 -
Optimizing Treatment on Idiopathic Inflammatory Myopathies
|
||
| Recruiting |
NCT05199246 -
Assessment of Safety and Acute Effects of a Lower-limb Powered Dermoskeleton in Patients With Neuromuscular Disorders
|
N/A | |
| Not yet recruiting |
NCT04034199 -
Treating Idiopathic Inflammatory Myopathies Related Reduced Bone Mineral Density With Denosumab or Zoledronic Acid
|
Phase 3 |